In human colon cancer, doxorubicin resistance is associated with the acquisition of an epithelial–mesenchymal transition, triggering the expression of VIME, N-cadherin, and Snail and Slug expression in resistant cells (HCT 168) [68], while in MDR human breast cancer (resistant to taxotere, epirubicin, and cyclophosphamide), VIME was significantly down-regulated [69]. The gene discussed is SNAI2; the disease is breast carcinoma.